Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype

44
14
Favorite

Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype

Seeking Alpha2022-02-18

The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（14）

xiaojn
·2022-02-18
Ok
Reply
3
Report
AsherA
·2022-02-18
Like pls
Reply
3
Report
Nue
·2022-02-18
Cool
Reply
4
Report
RK0948
·2022-02-18
Potentially buy in and sell out with 6 - 8%
Reply
2
Report
Megaverse
·2022-02-18
👌🏼 yea
Reply
2
Report
Delvin
·2022-02-18
I think good things
Reply
4
Report
whoartthou
·2022-02-18
C
Reply
4
Report
ShinChan89
·2022-02-18
Yes
Reply
5
Report
EverSys
·2022-02-18
Like
Reply
4
Report
Diamondhand6
·2022-02-18
K
Reply
5
Report
DancingOwl
·2022-02-18
Like and comment thanks
Reply
5
Report
Cubic
·2022-02-18
Like
Reply
3
Report
benjaminlsk
·2022-02-18
Nice
Reply
3
Report
ragdoll99
·2022-02-18
Please like thanks
Reply
4
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1150510845?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-18 18:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150510845","market":"us","top_or_hot":-1,"title":"Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype","media":"Seeking Alpha","content":"<div>\n<p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...</p>\n\n<a href=\"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-18 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...</p>\n\n<a href=\"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMY","symbol_name":"施贵宝","start_time":0,"source_url":"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype","article_id":"1150510845","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150510845","pubTimestamp":1645181612,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myer","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BMY":"施贵宝"},"translate_title":"Bristol Myers的Breyanzi获得FDA优先审查用于血癌亚型","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":0.9},"content_text":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.The FDA is expected to make a decision by June 24.The company's supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9094523449,"gmtCreate":1645189688979,"gmtModify":1676534006971,"author":{"id":"3554893275482082","authorId":"3554893275482082","name":"xiaojn","avatar":"https://static.tigerbbs.com/1d013f63de4e09aaf06a8ae8cf90aeb8","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3554893275482082","authorIdStr":"3554893275482082"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094523449","repostId":1150510845,"repostType":4,"repost":{"id":"1150510845","kind":"news","pubTimestamp":1645181612,"share":"https://ttm.financial/m/news/1150510845?lang=&edition=fundamental","pubTime":"2022-02-18 18:53","market":"us","language":"en","title":"Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype","url":"https://stock-news.laohu8.com/highlight/detail?id=1150510845","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myer","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of <a href=\"https://laohu8.com/S/BMY\">Bristol Myers Squibb&#39;s </a> Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.</p><p>The FDA is expected to make a decision by June 24.</p><p>The company&#39;s supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.</p><p>The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.</p><p>Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.</p><p>The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-18 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...</p>\n\n<a href=\"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150510845","content_text":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.The FDA is expected to make a decision by June 24.The company's supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094582630,"gmtCreate":1645183778086,"gmtModify":1676534006602,"author":{"id":"3581899667853665","authorId":"3581899667853665","name":"AsherA","avatar":"https://static.tigerbbs.com/2302a91d58b23f78216a0958dfecfcf6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581899667853665","authorIdStr":"3581899667853665"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094582630","repostId":1150510845,"repostType":4,"repost":{"id":"1150510845","kind":"news","pubTimestamp":1645181612,"share":"https://ttm.financial/m/news/1150510845?lang=&edition=fundamental","pubTime":"2022-02-18 18:53","market":"us","language":"en","title":"Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype","url":"https://stock-news.laohu8.com/highlight/detail?id=1150510845","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myer","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of <a href=\"https://laohu8.com/S/BMY\">Bristol Myers Squibb&#39;s </a> Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.</p><p>The FDA is expected to make a decision by June 24.</p><p>The company&#39;s supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.</p><p>The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.</p><p>Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.</p><p>The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-18 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...</p>\n\n<a href=\"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150510845","content_text":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.The FDA is expected to make a decision by June 24.The company's supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094582876,"gmtCreate":1645183741988,"gmtModify":1676534006603,"author":{"id":"3583038013988308","authorId":"3583038013988308","name":"Nue","avatar":"https://static.tigerbbs.com/b8345100cc574b68844750cc9debaa37","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583038013988308","authorIdStr":"3583038013988308"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094582876","repostId":1150510845,"repostType":4,"repost":{"id":"1150510845","kind":"news","pubTimestamp":1645181612,"share":"https://ttm.financial/m/news/1150510845?lang=&edition=fundamental","pubTime":"2022-02-18 18:53","market":"us","language":"en","title":"Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype","url":"https://stock-news.laohu8.com/highlight/detail?id=1150510845","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myer","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of <a href=\"https://laohu8.com/S/BMY\">Bristol Myers Squibb&#39;s </a> Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.</p><p>The FDA is expected to make a decision by June 24.</p><p>The company&#39;s supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.</p><p>The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.</p><p>Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.</p><p>The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-18 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...</p>\n\n<a href=\"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150510845","content_text":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.The FDA is expected to make a decision by June 24.The company's supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094582097,"gmtCreate":1645183644981,"gmtModify":1676534006587,"author":{"id":"3572004565657160","authorId":"3572004565657160","name":"RK0948","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":8,"crmLevelSwitch":1,"idStr":"3572004565657160","authorIdStr":"3572004565657160"},"htmlText":"Potentially buy in and sell out with 6 - 8%","listText":"Potentially buy in and sell out with 6 - 8%","text":"Potentially buy in and sell out with 6 - 8%","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094582097","repostId":1150510845,"repostType":4,"repost":{"id":"1150510845","kind":"news","pubTimestamp":1645181612,"share":"https://ttm.financial/m/news/1150510845?lang=&edition=fundamental","pubTime":"2022-02-18 18:53","market":"us","language":"en","title":"Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype","url":"https://stock-news.laohu8.com/highlight/detail?id=1150510845","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myer","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of <a href=\"https://laohu8.com/S/BMY\">Bristol Myers Squibb&#39;s </a> Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.</p><p>The FDA is expected to make a decision by June 24.</p><p>The company&#39;s supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.</p><p>The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.</p><p>Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.</p><p>The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-18 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...</p>\n\n<a href=\"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150510845","content_text":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.The FDA is expected to make a decision by June 24.The company's supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094586920,"gmtCreate":1645183243079,"gmtModify":1676534006571,"author":{"id":"3576278607547570","authorId":"3576278607547570","name":"Megaverse","avatar":"https://static.itradeup.com/news/0bc7f9365fb6866c5d290efdfb79d160","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576278607547570","authorIdStr":"3576278607547570"},"htmlText":"👌🏼 yea&nbsp;","listText":"👌🏼 yea&nbsp;","text":"👌🏼 yea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094586920","repostId":1150510845,"repostType":4,"repost":{"id":"1150510845","kind":"news","pubTimestamp":1645181612,"share":"https://ttm.financial/m/news/1150510845?lang=&edition=fundamental","pubTime":"2022-02-18 18:53","market":"us","language":"en","title":"Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype","url":"https://stock-news.laohu8.com/highlight/detail?id=1150510845","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myer","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of <a href=\"https://laohu8.com/S/BMY\">Bristol Myers Squibb&#39;s </a> Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.</p><p>The FDA is expected to make a decision by June 24.</p><p>The company&#39;s supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.</p><p>The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.</p><p>Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.</p><p>The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-18 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...</p>\n\n<a href=\"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150510845","content_text":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.The FDA is expected to make a decision by June 24.The company's supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094588773,"gmtCreate":1645183170577,"gmtModify":1676534006563,"author":{"id":"3575200533809324","authorId":"3575200533809324","name":"Delvin","avatar":"https://static.tigerbbs.com/93738020b8156486e54265bfacf43f4b","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3575200533809324","authorIdStr":"3575200533809324"},"htmlText":"I think good things","listText":"I think good things","text":"I think good things","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094588773","repostId":1150510845,"repostType":4,"repost":{"id":"1150510845","kind":"news","pubTimestamp":1645181612,"share":"https://ttm.financial/m/news/1150510845?lang=&edition=fundamental","pubTime":"2022-02-18 18:53","market":"us","language":"en","title":"Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype","url":"https://stock-news.laohu8.com/highlight/detail?id=1150510845","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myer","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of <a href=\"https://laohu8.com/S/BMY\">Bristol Myers Squibb&#39;s </a> Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.</p><p>The FDA is expected to make a decision by June 24.</p><p>The company&#39;s supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.</p><p>The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.</p><p>Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.</p><p>The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-18 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...</p>\n\n<a href=\"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150510845","content_text":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.The FDA is expected to make a decision by June 24.The company's supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094588491,"gmtCreate":1645183163094,"gmtModify":1676534006556,"author":{"id":"3581653518216493","authorId":"3581653518216493","name":"whoartthou","avatar":"https://static.tigerbbs.com/255e220c4fd45d829d979119233c8196","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3581653518216493","authorIdStr":"3581653518216493"},"htmlText":"C","listText":"C","text":"C","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094588491","repostId":1150510845,"repostType":4,"repost":{"id":"1150510845","kind":"news","pubTimestamp":1645181612,"share":"https://ttm.financial/m/news/1150510845?lang=&edition=fundamental","pubTime":"2022-02-18 18:53","market":"us","language":"en","title":"Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype","url":"https://stock-news.laohu8.com/highlight/detail?id=1150510845","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myer","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of <a href=\"https://laohu8.com/S/BMY\">Bristol Myers Squibb&#39;s </a> Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.</p><p>The FDA is expected to make a decision by June 24.</p><p>The company&#39;s supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.</p><p>The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.</p><p>Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.</p><p>The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-18 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...</p>\n\n<a href=\"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150510845","content_text":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.The FDA is expected to make a decision by June 24.The company's supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094588843,"gmtCreate":1645183079998,"gmtModify":1676534006548,"author":{"id":"3581763751831637","authorId":"3581763751831637","name":"ShinChan89","avatar":"https://static.tigerbbs.com/93838fdb97783c72aa29aef28ea94143","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581763751831637","authorIdStr":"3581763751831637"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094588843","repostId":1150510845,"repostType":4,"repost":{"id":"1150510845","kind":"news","pubTimestamp":1645181612,"share":"https://ttm.financial/m/news/1150510845?lang=&edition=fundamental","pubTime":"2022-02-18 18:53","market":"us","language":"en","title":"Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype","url":"https://stock-news.laohu8.com/highlight/detail?id=1150510845","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myer","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of <a href=\"https://laohu8.com/S/BMY\">Bristol Myers Squibb&#39;s </a> Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.</p><p>The FDA is expected to make a decision by June 24.</p><p>The company&#39;s supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.</p><p>The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.</p><p>Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.</p><p>The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-18 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...</p>\n\n<a href=\"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150510845","content_text":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.The FDA is expected to make a decision by June 24.The company's supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094588115,"gmtCreate":1645182944987,"gmtModify":1676534006540,"author":{"id":"3562717829058854","authorId":"3562717829058854","name":"EverSys","avatar":"https://static.tigerbbs.com/11a08d675c0a4f706a53d64244901417","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":5,"crmLevelSwitch":0,"idStr":"3562717829058854","authorIdStr":"3562717829058854"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094588115","repostId":1150510845,"repostType":4,"repost":{"id":"1150510845","kind":"news","pubTimestamp":1645181612,"share":"https://ttm.financial/m/news/1150510845?lang=&edition=fundamental","pubTime":"2022-02-18 18:53","market":"us","language":"en","title":"Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype","url":"https://stock-news.laohu8.com/highlight/detail?id=1150510845","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myer","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of <a href=\"https://laohu8.com/S/BMY\">Bristol Myers Squibb&#39;s </a> Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.</p><p>The FDA is expected to make a decision by June 24.</p><p>The company&#39;s supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.</p><p>The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.</p><p>Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.</p><p>The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-18 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...</p>\n\n<a href=\"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150510845","content_text":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.The FDA is expected to make a decision by June 24.The company's supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094581343,"gmtCreate":1645182681021,"gmtModify":1676534006516,"author":{"id":"3568696694714874","authorId":"3568696694714874","name":"Diamondhand6","avatar":"https://static.tigerbbs.com/3d95004a1d764b1b82eacaa7b9537269","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3568696694714874","authorIdStr":"3568696694714874"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094581343","repostId":1150510845,"repostType":4,"repost":{"id":"1150510845","kind":"news","pubTimestamp":1645181612,"share":"https://ttm.financial/m/news/1150510845?lang=&edition=fundamental","pubTime":"2022-02-18 18:53","market":"us","language":"en","title":"Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype","url":"https://stock-news.laohu8.com/highlight/detail?id=1150510845","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myer","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of <a href=\"https://laohu8.com/S/BMY\">Bristol Myers Squibb&#39;s </a> Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.</p><p>The FDA is expected to make a decision by June 24.</p><p>The company&#39;s supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.</p><p>The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.</p><p>Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.</p><p>The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-18 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...</p>\n\n<a href=\"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150510845","content_text":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.The FDA is expected to make a decision by June 24.The company's supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094581912,"gmtCreate":1645182640848,"gmtModify":1676534006516,"author":{"id":"3586053409735009","authorId":"3586053409735009","name":"DancingOwl","avatar":"https://static.tigerbbs.com/dde4a3d6bbb288433e036b7096329e39","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586053409735009","authorIdStr":"3586053409735009"},"htmlText":"Like and comment thanks&nbsp;","listText":"Like and comment thanks&nbsp;","text":"Like and comment thanks","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094581912","repostId":1150510845,"repostType":4,"repost":{"id":"1150510845","kind":"news","pubTimestamp":1645181612,"share":"https://ttm.financial/m/news/1150510845?lang=&edition=fundamental","pubTime":"2022-02-18 18:53","market":"us","language":"en","title":"Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype","url":"https://stock-news.laohu8.com/highlight/detail?id=1150510845","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myer","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of <a href=\"https://laohu8.com/S/BMY\">Bristol Myers Squibb&#39;s </a> Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.</p><p>The FDA is expected to make a decision by June 24.</p><p>The company&#39;s supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.</p><p>The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.</p><p>Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.</p><p>The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-18 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...</p>\n\n<a href=\"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150510845","content_text":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.The FDA is expected to make a decision by June 24.The company's supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094581086,"gmtCreate":1645182637407,"gmtModify":1676534006508,"author":{"id":"4087209385013010","authorId":"4087209385013010","name":"Cubic","avatar":"https://static.tigerbbs.com/d3d074ffac2ae61d6f86b7a56db542f7","vip":1,"hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","crmLevel":4,"crmLevelSwitch":0,"idStr":"4087209385013010","authorIdStr":"4087209385013010"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094581086","repostId":1150510845,"repostType":4,"repost":{"id":"1150510845","kind":"news","pubTimestamp":1645181612,"share":"https://ttm.financial/m/news/1150510845?lang=&edition=fundamental","pubTime":"2022-02-18 18:53","market":"us","language":"en","title":"Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype","url":"https://stock-news.laohu8.com/highlight/detail?id=1150510845","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myer","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of <a href=\"https://laohu8.com/S/BMY\">Bristol Myers Squibb&#39;s </a> Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.</p><p>The FDA is expected to make a decision by June 24.</p><p>The company&#39;s supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.</p><p>The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.</p><p>Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.</p><p>The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-18 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...</p>\n\n<a href=\"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150510845","content_text":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.The FDA is expected to make a decision by June 24.The company's supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094583980,"gmtCreate":1645182478932,"gmtModify":1676534006485,"author":{"id":"3571707309049146","authorId":"3571707309049146","name":"benjaminlsk","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/ae1f49570794979e009a5efdeb6f4789","crmLevel":1,"crmLevelSwitch":0,"idStr":"3571707309049146","authorIdStr":"3571707309049146"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094583980","repostId":1150510845,"repostType":4,"repost":{"id":"1150510845","kind":"news","pubTimestamp":1645181612,"share":"https://ttm.financial/m/news/1150510845?lang=&edition=fundamental","pubTime":"2022-02-18 18:53","market":"us","language":"en","title":"Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype","url":"https://stock-news.laohu8.com/highlight/detail?id=1150510845","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myer","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of <a href=\"https://laohu8.com/S/BMY\">Bristol Myers Squibb&#39;s </a> Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.</p><p>The FDA is expected to make a decision by June 24.</p><p>The company&#39;s supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.</p><p>The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.</p><p>Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.</p><p>The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-18 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...</p>\n\n<a href=\"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150510845","content_text":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.The FDA is expected to make a decision by June 24.The company's supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094589859,"gmtCreate":1645182126222,"gmtModify":1676534006484,"author":{"id":"3575877970346052","authorId":"3575877970346052","name":"ragdoll99","avatar":"https://static.tigerbbs.com/4b59eb72cfa88792118276743490208d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575877970346052","authorIdStr":"3575877970346052"},"htmlText":"Please like thanks","listText":"Please like thanks","text":"Please like thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094589859","repostId":1150510845,"repostType":4,"repost":{"id":"1150510845","kind":"news","pubTimestamp":1645181612,"share":"https://ttm.financial/m/news/1150510845?lang=&edition=fundamental","pubTime":"2022-02-18 18:53","market":"us","language":"en","title":"Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype","url":"https://stock-news.laohu8.com/highlight/detail?id=1150510845","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myer","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of <a href=\"https://laohu8.com/S/BMY\">Bristol Myers Squibb&#39;s </a> Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.</p><p>The FDA is expected to make a decision by June 24.</p><p>The company&#39;s supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.</p><p>The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.</p><p>Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.</p><p>The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers' Breyanzi Gets FDA Priority Review for Expanded Use in Blood Cancer Subtype\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-18 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell ...</p>\n\n<a href=\"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150510845","content_text":"The U.S. Food and Drug Administration (FDA) granted priority review for expanded use of Bristol Myers Squibb's  Breyanzi as a second line treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after failure of first-line therapy.The FDA is expected to make a decision by June 24.The company's supplemental biologics license application was backed by data from a phase 3 trial, dubbed TRANSFORM.The company said that in the trial Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years.Breyanzi is approved in the U.S. to treat adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.The drug also carries a Boxed Warning for the risks of cytokine release syndrome and neurologic toxicities and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":44,"commentSize":14,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}